Overview

Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This superiority of central pressure versus peripheral measures to predict cardiovascular events has also been reported in general population or in elder people
Phase:
Phase 4
Details
Lead Sponsor:
IInstituto Gallego de Medicina Vascular
Treatments:
Dapagliflozin
Glimepiride